Showing 1351-1360 of 1535 results for "".
- Galderma's OTC Differin Gel Hits Store Shelveshttps://practicaldermatology.com/news/galdermas-otc-differin-gel-hits-stores/2458299/Galderma’s Differin Gel 0.1% (adapalene) is now available over the counter (OTC) at major retail and drug stores. Galderma officially launched the gel at a New York City media fete, and the skin care co
- FDA OKs Coolsculpting for Upper Arm Fat Reductionhttps://practicaldermatology.com/news/fda-oks-coolsculpting-for-upper-arm-fat-reduction/2458300/ZELTIQ® Aesthetics, Inc.’s CoolSculpting is now US Food and Drug Administration (FDA)-cleared for fat reduction in the upper arms.
- New Compound May Block Spread of Melanoma, Treat Sclerodermahttps://practicaldermatology.com/news/new-compound-may-block-spread-of-melanoma-treat-scleroderma/2458329/A chemical compound, and potential new drug, may reduce the spread of melanoma cells by up to 90 percent, report researchers from Michigan State University in East Lansing. The man-made, small-molecule drug compound goes after a gene’s ability to produce RNA molecules and certain pr
- Carmex Rolls Out New Comfort Care Lip Balmshttps://practicaldermatology.com/news/carmex-rolls-out-new-comfort-care-lip-balms/2458343/Harsh winter weather can wreak havoc on the lips, leaving them dry, chapped and irritated. New CARMEX COMFORT CARE™ lip balms can help, says New York City dermatologist Neil Sadick, MD at a media event. Launched in late 2016, the new line is fo
- FDA Approved Eucrisa (Crisaborole) for ADhttps://practicaldermatology.com/news/fda-approved-eucrisa-crisaborole-for-ad/2458344/The U.S. Food and Drug Administration approved Eucrisa (crisaborole) ointment to treat mild-to-moderate eczema in patients two years of age and older. Eucrisa, applied topically twice daily, is a phosphodiesterase 4 (PDE-4) i
- AnaptysBio, Inc.'s IL-33-Blocker Cleared for Phase 2a Trials in AD, Peanut Allergyhttps://practicaldermatology.com/news/anaptysbio-incs-il-33-blocker-cleared-for-phase-2a-trials-in-ad-peanut-allergy/2458347/The United Kingdom Medicines and Healthcare Products Regulatory Agency has green lighted a Phase 2a clinical trial for AnaptysBio, Inc.’s ANB020 for the treatment of adults with moderate-to-severe atopic dermatitis. The United States Food and Drug Ad
- CDC Study: Banning Indoor Tanning Among Minors Will Save Lives, Moneyhttps://practicaldermatology.com/news/banning-indoor-tanning-among-minors-will-save-lives-money/2458354/An age restriction on indoor tanning could save thousands of lives and millions of dollars, according to new research published online in the Journal of the American Academy of Dermatology. In December 2015, the U.S. Food and Drug Administration
- New from Topix: Replenix® Pure Hydration Moisture Balmhttps://practicaldermatology.com/news/new-from-topix-replenix-pure-hydration-moisture-balm/2458368/The latest from Topix Pharmaceuticals, Inc., Replenix® Pure Hydration Moisture Balm, targets dry and aging skin. Various molecular weights of Hyaluronic Acid draw moisture into the skin and work with Yucca Glauca
- FDA OKS Santalis' Phase 2 Study of EISO For ADhttps://practicaldermatology.com/news/fda-oks-santalis-phase-2-study-of-eiso-in-ad/2458385/The U.S. Food and Drug Administration (FDA) has green lighted Santalis Pharmaceuticals Phase 2 clinical study of East Indian Sandalwood Oil (EISO) cream for the treatment of atopic dermatitis (AD). The multi-center, placebo controlled, double blinded, Phase 2 efficacy and tolerability stu
- Biofrontera Launches Ameluz for Actinic Keratosishttps://practicaldermatology.com/news/biofrontera-launches-ameluz-for-actinic-keratosis/2458397/Biofrontera AG initiated the US commercial launch of its combination topical prescription drug Ameluz and medical device BF-RhodoLED, which has been FDA approved to treat mild to moderate actinic keratosis (AK) on the face and scalp. Ameluz is used in combination with the medical device B